Mårten Segelmark
81 – 90 of 188
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis versus the general population
(
- Contribution to journal › Article
-
Mark
Home- or Institutional Hemodialysis? - a Matched Pair-Cohort Study Comparing Survival and Some Modifiable Factors Related to Survival
(
- Contribution to journal › Article
-
Mark
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA)
(
- Contribution to journal › Scientific review
-
Mark
Neutrophil extracellular traps in ANCA-associated vasculitis
(
- Contribution to journal › Scientific review
-
Mark
IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article
-
Mark
Long-term kidney transplant outcomes in primary glomerulonephritis : Analysis from the ERA-EDTA registry
(
- Contribution to journal › Article
-
Mark
Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period
(
- Contribution to journal › Article
- 2015
-
Mark
Circulating microRNA expression pattern separates patients with anti-neutrophil cytoplasmic antibody associated vasculitis from healthy controls.
(
- Contribution to journal › Article